Harpoon Therapeutics Stock Fair Value Calculator – Harpoon Therapeutics Files to Sell 25.75M Common Shares for Shareholders

☀️Trending News

Harpoon Therapeutics ($NASDAQ:HARP), Inc. is a clinical-stage biopharmaceutical company focused on developing novel, proprietary T cell engaging biotherapeutics for the treatment of cancer and other diseases. The company recently filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for the potential sale of up to 25.75 million of its common shares by certain stockholders. The stockholders including Alta Partners, Omega Funds and BVF Partners L.P. have registered for resale of their shares through the SEC filing.

Harpoon Therapeutics plans to use the proceeds from the sale of shares for general corporate purposes, including research and development activities, working capital needs, as well as, potential acquisitions or investments in other companies or technologies, if any. The company has not yet determined the price range for such shares that are being offered in the registration statement, and there can be no assurance as to when or if the offering will be completed.

Share Price

On Friday, Harpoon Therapeutics filed to sell 25.75 million common shares in a bid to benefit its shareholders. In response to this filing, the company’s stock opened at $10.3 and closed at $8.9, plunging by 10.6 per cent from its previous closing price of $10.0. This sharp decline in the company’s stock is likely a result of investors expecting the release of new shares to have a negative impact on the company’s current market value.

As such, they sold their existing stocks quickly in order to avoid the potential risks associated with the new shares. This filing from Harpoon Therapeutics is likely to have a significant impact on the company’s share price in the short-term, but only time will tell how well it fares in the long run. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Harpoon Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Harpoon Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Harpoon Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Harpoon Therapeutics are shown below. More…

Analysis – Harpoon Therapeutics Stock Fair Value Calculator

At GoodWhale, we have conducted an analysis of HARPOON THERAPEUTICS‘s fundamentals and have calculated the intrinsic value of their share to be around $17.1. This is based on our proprietary Valuation Line which takes into account the company’s financials and performance indicators. At the moment, the stock is trading at $8.9, meaning it is currently undervalued by 48.1%. This presents a great opportunity for investors to benefit from a potential future upswing in the stock price. It is a great time to consider investing in HARPOON THERAPEUTICS if you are looking for a potential growth stock. More…

Peers

The company’s pipeline includes two Phase 1 clinical trials for its lead product, HPN424, and a Phase 2 clinical trial for HPN536. Harpoon’s competitors include BrightPath Biotherapeutics Co Ltd, Talaris Therapeutics Inc, and F-Star Therapeutics Inc.

– BrightPath Biotherapeutics Co Ltd ($TSE:4594)

BrightPath Biotherapeutics Co Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of cancer. The company’s lead product candidate is BH-301, a novel immunotherapy that is in clinical development for the treatment of solid tumors. BrightPath Biotherapeutics Co Ltd has a market cap of 7.71B as of 2022, a Return on Equity of -43.51%. The company’s focus on developing innovative therapies for the treatment of cancer makes it a compelling investment opportunity for investors interested in the healthcare sector.

– Talaris Therapeutics Inc ($NASDAQ:TALS)

Talaris Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing a proprietary cell therapy platform to treat patients with autoimmune diseases, inflammatory disorders and blood-based cancers. The Company’s product candidates include T cell receptor (TCR) modified T cells, natural killer (NK) cells, and CAR T cells. Talaris Therapeutics Inc is headquartered in Cambridge, Massachusetts.

– F-star Therapeutics Inc ($NASDAQ:FSTX)

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company, which engages in the research and development of novel antibody therapeutics. Its pipeline includes FS102, FS103, and FS404. The company was founded by Andrew J. Allen, Christoph A. Borner, and James P. Allison in 2016 and is headquartered in Cambridge, MA.

Summary

Harpoon Therapeutics is a biotechnology company focused on developing immunotherapies for the treatment of cancer and other diseases. On June 10th, the company filed to sell 25.75 million common shares, which resulted in the stock price dropping the same day. Investors considering investing in Harpoon Therapeutics should conduct their own research and make sure to assess the risks associated with investing in a biotechnology company. It is important to take into account the company’s current financial and operational state, as well as the potential for future growth.

Additionally, investors should pay attention to the company’s progress in developing its therapies and the effect of its product pipeline on its stock price.